Abstracts tagged "SLE"

Abstract Number: 2060 • 2016 ACR/ARHP Annual Meeting
Bim Suppresses the Development of SLE By Limiting Macrophage Inflammatory Responses
FuNien Tsai¹, Carla Cuda², Harris R. Perlman³, Philip J. Homan⁴, Salina Dominguez², Alexander Shaffer³, George Kenneth Haines III⁵ and Jack Hutcheson⁶, ¹Medicine-Rheumatology, Northwestern University-Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Chicago, IL, ³Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁴Medicine-Rheumatology, Northwestern University, Chicago, IL, ⁵Mount Sinai, New York, NY, ⁶UT Southwestern, Dallas, TX
Background/Purpose: The Bcl-2 family guards the mitochondrial apoptotic pathway. Among numerous Bcl-2 antagonists, only the loss of Bim in mice leads to the development of…
Abstract Number: 2864 • 2016 ACR/ARHP Annual Meeting
Identifying Dysregulated and Co-Dysregulated Markers in Systemic Lupus Erythematosus Using Multi-Modal Biomarker Data from a Large Pre-Clinical Study
Yanhua Sarah Hu¹, S Bandyopadhyay¹, Julie Carman², Nataly Manjarrez-Orduño², Can Jiang¹, Suzanne Suchard², Laurence Menard², sium habte¹, selena kansal¹, vivek jayaswal³, Richard A. Furie⁴ and Steven G. Nadler⁵, ¹Bristol-Myers Squibb, Princeton, NJ, ²Discovery Translational Sciences Group, Bristol-Myers Squibb, Princeton, NJ, ³Biocon Bristol-Myers Squibb Research Center, Bangalore, NJ, India, ⁴Division of Rheumatology, North Shore LIJ Health System, Great Neck, NY, ⁵Immunosciences Translational Research, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, relapsing autoimmune disease affecting multiple organs and is a highly heterogeneous condition, with wide variations in the…
Abstract Number: 3239 • 2016 ACR/ARHP Annual Meeting
Expression of IFN-Regulated Genes in Autoantibody Exposed Babies in Utero
Malin Hedlund¹, Gudny-Ella Thorlacius¹, Margarita Ivanchenko¹, Vijole Ottosson¹, Amina Ossoinak¹, Linda Lagnefeldt¹, Joanna Tingstrom¹, Alexander Espinosa¹, Lars Rönnblom², Maija-Leena Eloranta², Sven-Erik Sonesson¹ and Marie Wahren-Herlenius³, ¹Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Stockholm, Sweden, ²Uppsala University, Department of Medical Sciences, Rheumatology and Science for Life Laboratory, Uppsala, Sweden, ³Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Ro/SSA autoantibodies and an IFN signature are commonly present in women with Sjögren’s syndrome and SLE. During pregnancy, the autoantibodies are transported across the…
Abstract Number: 769 • 2016 ACR/ARHP Annual Meeting
Response to Belimumab in SLE Patients with High Disease Activity: Data from a Multicentric Clinical-Practice Based Study Cohort
Luca Iaccarino¹, Silvano Bettio², Rossella Reggia³, Giacomo Emmi⁴, Fulvia Ceccarelli⁵, Chiara Tani⁶, Maria Gerosa⁷, Marcello Govoni⁸, Alesandra Bortoluzzi⁹, Salvatore De Vita¹⁰, Ginevra De Marchi¹¹, Rossella De Angelis¹², Andrea Di Matteo¹², Carlo Salvarani¹³, Giulia Pazzola¹³, Elena Bartoloni-Bocci¹⁴, Laura Andreoli¹⁵, Margherita Zen¹⁶, Fabrizio Conti¹⁷, Marta Mosca⁶, Pier Luigi Meroni¹⁸, Roberto Gerli¹⁴, Angela Tincani¹⁹, Andrea Doria²⁰ and Lorenzo Emmi²¹, ¹Department of Medicine-DIMED, University of Padova, Padova, Italy, ²Rheumatology Unit, Univeristy of Padova, Padova, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁴Medical Pathology, Careggi University Hospital, Firenze, Italy, ⁵Sapienza University of Rome, Rome, Italy, ⁶Rheumatology Unit, University of Pisa, Pisa, Italy, ⁷University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁸Medical Sciences, UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ⁹UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ¹⁰Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia", Udine, Italy, Udine, Italy, ¹¹Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, ¹²Polytechnic university of Marche, Rheumatologic Clinic, Iesi, Italy, ¹³Rheumatology Unit, Internal Medicine Department, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ¹⁴Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ¹⁵University of Brescia, Spedali Civili, Brescia, Italy, ¹⁶Division of Rheumatology, University of Padova, Padova, Italy, ¹⁷Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ¹⁸Rheumatology Department, University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ¹⁹Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Italy, ²⁰Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ²¹Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic,, Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic, AOU Careggi, Florence, Italy
Background/Purpose: To investigate effectiveness and identify predictors of response to belimumab in patients with active SLE in clinical practice setting. Methods: One hundred eighty eight…
Abstract Number: 1121 • 2016 ACR/ARHP Annual Meeting
IFN Regulatory Factor-5 Signaling Increases IFN-Gamma Production and Suppresses IL-2 Production from CD4+ T Cells, and Controls IgG Production in B Cells
Kei Yasuda¹, Prachi Shukla², Ramon G. Bonegio¹ and Ian Rifkin¹, ¹Renal Section, Boston Univ Schl of Med, Boston, MA, ²Boston University School of Medicine, Boston, MA
Background/Purpose: Recent studies of human genetics and mouse models have shown that interferon regulatory factor-5 (IRF5) is associated with the development of autoimmune disease. However,…
Abstract Number: 1768 • 2016 ACR/ARHP Annual Meeting
Fatigue in SLE Is Associated with Neuropsychiatric Involvement, Pain, Impaired Sleep and a Reduced Quality of Life
Andreas Jönsen¹, Pia C Sundgren², Jessika Nystedt³, Petra Nilsson³, Åsa Lilja⁴ and Anders A. Bengtsson¹, ¹Lund University, Department of Clinical Sciences, Rheumatology, Lund, Sweden, ²Department of Diagnostic Radiology, Lund University, Lund, Sweden, ³Department of Clinical Sciences, Neurology, Lund University, Lund, Sweden, ⁴Center for Primary Health Care Research, Lund University, Malmö, Sweden
Background/Purpose: Fatigue is a major patient complaint in SLE, often severely impacting quality of life and activities including work. In this study, we analyze neuropsychiatric…
Abstract Number: 2064 • 2016 ACR/ARHP Annual Meeting
Blood and Kidney Molecular Profiles Distinguish Subjects with Lupus Nephritis from Other Kidney Disorders
Matteo Cesaroni¹, Jarrat Jordan¹, Marc Chevrier², Alan Perlman³, James M. Chevalier⁴, Thomas Parker³, Daniel Levine³, Surya V. Seshan⁵, Anna Gong⁶, Takahiro Sato¹ and Jacqueline Benson¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research and Development, LLC, Collegeville, PA, ³The Rogosin Institute,New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, NY, ⁴Nephrology, The Rogosin Institute New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, ⁵Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, NY, ⁶The Rogosin Institute,New York Presbyterian Hospital-Weill Medical College of Cornell University, new york, NY
Background/Purpose: Kidney biopsy remains the gold standard for diagnosis and staging of Lupus Nephritis (LN). Although kidney biopsies are commonly performed in the clinical setting,…
Abstract Number: 2869 • 2016 ACR/ARHP Annual Meeting
Critical Roles of IRAK4 Kinase Activity in Inflammation but Not B Cell Response in SLE
Chia Chi Sun¹, Gang Chen², Nuruddeen Lewis¹, Andrew T Bender¹, Changling Sia³, Ling Zhang², Catherine Jorand Lebrun⁴, Herbert Y Lin⁵, Ravi I Thadhani⁶, Harsukh Parmar¹ and Julie A DeMartino¹, ¹TIP Immunology, EMD Serono, Inc, Billerica, MA, ²EMD Serono, Inc, Billerica, MA, ³TIP Immunology, EMD Serono, Inc, Billeria, MA, ⁴Discovery Technology, EMD Serono, Inc, Billerica, MA, ⁵Division of Nephrology, Massachusetts General Hospital, Boston, MA, ⁶Divison of Nephrology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Interleukin-1 receptor (IL-1R)-associated kinase 4 (IRAK4) is a key component of the Myddosome complex, which is essential for signalling downstream of IL-1R and most…
Abstract Number: 3241 • 2016 ACR/ARHP Annual Meeting
Genetic Variation and Tobacco Smoke Exposure in Systemic Lupus Erythematosus: A Case Control Study Among African Americans
Bethany Wolf¹, Paula S. Ramos², Paul Nietert³, J. Madison Hyer¹, Viswanathan Ramakrishnan¹, Gary S. Gilkeson⁴, Gerard Hardiman² and Diane L. Kamen⁵, ¹Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²Medicine, Medical University of South Carolina, Charleston, SC, ³Public Health Science, Medical University of South Carolina, Charleston, SC, ⁴Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately affects African Americans, and the development of SLE is believed to be triggered by exposure to one or more…
Abstract Number: 770 • 2016 ACR/ARHP Annual Meeting
Introducing a Novel SLE-Specific IFN-I Inhibitor CNTO 6358: Laying the Groundwork for Precision Medicine in Lupus
Jarrat Jordan¹, Matteo Cesaroni¹, Jessica Schreiter¹, Chichi Huang², Tanesha Cash-Mason³, Marc Chevrier¹ and Jacqueline Benson¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Biologics Research, Janssen Research and Development, LLC., Spring House, PA, ³Cardiovascular and Metabolism Research, Janssen Research and Development, LLC., Spring House, PA
Background/Purpose: The type I interferon (IFN-I) family of cytokines signal through a ubiquitously expressed heterodimeric receptor (IFNAR) composed of IFNAR1 and the high-affinity binding chain…
Abstract Number: 1171 • 2016 ACR/ARHP Annual Meeting
Obesity and the Risk of Systemic Lupus Erythematosus in the Nurses’ Health Studies
Sara K. Tedeschi¹, Medha Barbhaiya¹, Bing Lu¹, Susan Malspeis², Jeffrey A. Sparks², Elizabeth W. Karlson¹, Walter C. Willett³ and Karen H. Costenbader¹, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Obesity has become alarmingly common over the past four decades in the U.S., with a notable rise in obesity prevalence starting in the late…
Abstract Number: 1775 • 2016 ACR/ARHP Annual Meeting
Smoking As a Predictor of Cutaneous Activity in Systemic Lupus Erythematosus
Shawn Kwatra¹, Michelle Petri² and Wei Fu³, ¹Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
ACR Abstract Authors: Shawn G. Kwatra1, Wei Fu2, Michelle Petri2 1Department of Dermatology, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD Title:…
Abstract Number: 2451 • 2016 ACR/ARHP Annual Meeting
Evaluation of Ovarian Reserve and Function in Adolescent Females with Systemic Lupus Erythematosus
Yonit Sterba¹, Tamara Tanner² and Dawn Wahezi¹, ¹Pediatric Rheumatology, The Children's Hospital at Montefiore, Bronx, NY, ²Pediatrics, The Children's Hospital at Montefiore, Bronx, NY
Background/Purpose: The onset of childhood systemic lupus erythematosus (cSLE) most frequently occurs after age 12. Studies in adolescents with cSLE suggest that ovarian dysfunction may…
Abstract Number: 2871 • 2016 ACR/ARHP Annual Meeting
Unaffected Lupus Relatives Are Distinguished from SLE Patients and Unaffected Individuals Not Related to SLE Patients By Lupus-Specific Connective Tissue Disease Questionnaire Scores, Autoantibodies, and Distinct Soluble Mediators
Melissa E. Munroe¹, Kendra A. Young², Jill M. Norris², Teresa Aberle¹, Virginia C. Roberts¹, Joel M. Guthridge³, Diane L. Kamen⁴, Gary S. Gilkeson⁵, Michael Weisman⁶, Mariko Ishimori⁶, Daniel J Wallace⁷, David Karp⁸, Kathy L. Sivils¹, John B. Harley^9,10 and Judith A. James^11,12, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁹US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹⁰Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Childrens Hospital, Cincinnati, OH, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and select individuals for prevention trials. Blood relatives (Rel) of lupus patients…
Abstract Number: 3242 • 2016 ACR/ARHP Annual Meeting
Identification and Functional Characterization of TNIP1 Causal Variants Associated with Systemic Lupus Erythematosus
Satish Pasula¹, Mandi Wiley¹, Ying-yu Wu¹, Ajay Nair¹, Jaanam Gopalakrishnan² and Patrick M. Gaffney¹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by autoantibody production and dysregulated interferon responses. Genome-wide association studies (GWAS) have identified more…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].